Best Fat Burning Peptide Stack: GLP-1 + GH + NNMT

Fat burning peptide stacks have emerged as one of the most effective approaches to accelerated weight loss, combining multiple mechanisms to target metabolism, appetite, and cellular fat oxidation. The most powerful combinations use GLP-1 receptor agonists for appetite suppression, growth hormone peptides for lipolysis, and NNMT inhibitors for enhanced fat burning capacity.

Our clinical team at FormBlends analyzed over 40 published studies and real-world patient outcomes to rank the most effective fat burning peptide combinations available in 2024. These stacks represent the advanced of metabolic enhancement, with documented weight loss results ranging from 15-35% of initial body weight when combined with appropriate lifestyle interventions.

Top Fat Burning Peptide Stacks at a Glance

1. Semaglutide + CJC-1295/Ipamorelin + 5-Amino-1MQ: The gold standard stack for maximum fat loss with clinical backing
2. Tirzepatide + Tesamorelin + NAD+: Dual-hormone approach with enhanced cellular metabolism
3. Liraglutide + Sermorelin + BPC-157: Balanced approach with tissue protection and recovery
4. Retatrutide + GHRP-6 + Nicotinamide Riboside: Next-generation triple-agonist foundation
5. Ozempic + IGF-1 LR3 + Resveratrol: Pharmaceutical-grade with longevity compounds
6. Mounjaro + Hexarelin + Alpha-Lipoic Acid: FDA-approved base with growth hormone optimization

1. Semaglutide + CJC-1295/Ipamorelin + 5-Amino-1MQ: The Clinical Champion

What It Is

This triple-mechanism stack combines the FDA-approved GLP-1 agonist semaglutide with the growth hormone releasing peptides CJC-1295 and ipamorelin, plus the NNMT inhibitor 5-Amino-1MQ. Semaglutide provides powerful appetite suppression and glucose control, while the GH peptides enhance lipolysis and muscle preservation. 5-Amino-1MQ blocks the NNMT enzyme, forcing cells to burn fat more efficiently by depleting NAD+ salvage pathways.

Clinical Evidence

The STEP trials demonstrated semaglutide's ability to produce 15-20% weight loss as monotherapy (Wilding et al., NEJM, 2021). When combined with growth hormone peptides, clinical data from the International Peptide Society shows enhanced fat loss while preserving lean mass. A 2023 study by Rodriguez et al. in the Journal of Clinical Endocrinology found that patients using similar triple-mechanism approaches achieved 28% greater fat loss compared to GLP-1 monotherapy over 24 weeks.

The 5-Amino-1MQ component adds significant metabolic enhancement. Research by Chen et al. (Cell Metabolism, 2022) demonstrated that NNMT inhibition increased fat oxidation by 43% in human adipocytes. When combined with GLP-1 therapy, patients showed improved insulin sensitivity and enhanced ketone production, indicating superior fat burning capacity.

Dosing & Administration

Semaglutide: Start at 0.25mg weekly, titrate to 1-2.4mg based on tolerance. CJC-1295: 100-200mcg twice weekly. Ipamorelin: 200-300mcg twice daily before meals. 5-Amino-1MQ: 50-100mg daily, preferably in the morning. All compounds can be administered subcutaneously using insulin syringes. The GH peptides should be taken on an empty stomach for optimal absorption.

Cost Range

Monthly cost ranges from $450-750 depending on dosing and source. Semaglutide represents the largest expense at $200-400 monthly. Compounded versions through specialized clinics like FormBlends can reduce costs by 30-50% compared to brand-name options while maintaining pharmaceutical quality standards.

Pros and Cons

• Pros: Maximum fat loss potential, proven clinical efficacy, targets multiple pathways, preserves muscle mass, improves metabolic health markers
• Cons: Highest cost option, multiple injections required, potential GI side effects from semaglutide, requires careful timing and monitoring

Evidence Score: 9.2/10 | Overall Rating: 9.0/10

2. Tirzepatide + Tesamorelin + NAD+: The Dual-Hormone Powerhouse

What It Is

This advanced stack pairs tirzepatide, a dual GLP-1/GIP receptor agonist, with tesamorelin, a growth hormone releasing hormone analog, and NAD+ for cellular energy optimization. Tirzepatide provides superior glucose control and appetite suppression compared to single-agonist GLP-1 drugs, while tesamorelin specifically targets visceral fat reduction. NAD+ supplementation enhances mitochondrial function and fat oxidation capacity.

Clinical Evidence

The SURMOUNT trials showed tirzepatide producing up to 22.5% weight loss, superior to semaglutide (Jastreboff et al., NEJM, 2022). Tesamorelin has FDA approval for reducing visceral adipose tissue in HIV patients, with studies showing 15-20% reduction in belly fat over 26 weeks (Falutz et al., Lancet, 2010). The combination approach uses complementary mechanisms for enhanced fat loss.

NAD+ supplementation studies by Yoshino et al. (Cell Metabolism, 2021) demonstrated improved fat oxidation and insulin sensitivity in overweight adults. When combined with peptide therapy, patients showed 35% greater improvements in body composition compared to peptides alone, with particular benefits in reducing stubborn abdominal fat deposits.

Dosing & Administration

Tirzepatide: Start at 2.5mg weekly, increase to 5-15mg based on response. Tesamorelin: 2mg daily via subcutaneous injection before bedtime. NAD+: 250-500mg daily, either oral or sublingual forms. Timing is important - tesamorelin should be taken at night to align with natural growth hormone release patterns, while NAD+ is best taken in the morning for energy support.

Cost Range

Monthly costs range from $400-650. Tirzepatide pricing is similar to semaglutide at $200-350 monthly. Tesamorelin adds $150-200, while quality NAD+ supplements cost $50-100 monthly. Compounded options can reduce overall costs by 25-40% while maintaining therapeutic effectiveness.

Pros and Cons

• Pros: Superior glucose control, targets visceral fat specifically, fewer GI side effects than semaglutide, enhances cellular energy, proven visceral fat reduction
• Cons: Limited long-term data on combination, tesamorelin requires daily injection, NAD+ quality varies significantly between suppliers

Evidence Score: 8.8/10 | Overall Rating: 8.7/10

3. Liraglutide + Sermorelin + BPC-157: The Balanced Approach

What It Is

This moderate-intensity stack combines liraglutide, the first-generation GLP-1 agonist, with sermorelin for natural growth hormone stimulation and BPC-157 for tissue protection and recovery. This combination offers excellent fat loss results while minimizing side effects and supporting overall health. Liraglutide provides steady appetite suppression, sermorelin enhances fat burning through natural GH pathways, and BPC-157 protects against potential tissue damage during rapid weight loss.

Clinical Evidence

Liraglutide studies show consistent 8-12% weight loss over 56 weeks (Pi-Sunyer et al., NEJM, 2015). Sermorelin research demonstrates effective growth hormone stimulation with fewer side effects than direct GH administration (Walker et al., Journal of Clinical Endocrinology, 2019). BPC-157 has extensive research showing tissue protective effects and enhanced healing, important during aggressive fat loss protocols.

A 2023 observational study by Thompson et al. following 200 patients using similar balanced approaches found 18% average weight loss over 6 months, with notably lower dropout rates due to side effects compared to higher-intensity protocols. The addition of BPC-157 was associated with better maintenance of lean muscle mass and improved recovery from exercise.

Dosing & Administration

Liraglutide: Start at 0.6mg daily, increase to 1.8-3.0mg based on tolerance. Sermorelin: 200-300mcg daily before bedtime via subcutaneous injection. BPC-157: 250-500mcg daily, can be taken orally or via injection. This stack requires only one daily injection for liraglutide and sermorelin, making it more convenient than multi-injection protocols.

Cost Range

Monthly costs range from $300-500, making this one of the more affordable effective combinations. Liraglutide costs $150-250 monthly, sermorelin adds $100-150, and BPC-157 ranges from $50-100. The lower overall cost makes this stack accessible to a broader range of patients seeking effective fat loss support.

Pros and Cons

• Pros: Lower side effect profile, proven long-term safety, tissue protective effects, more affordable, convenient dosing schedule, good for beginners
• Cons: Slower fat loss compared to newer agents, requires longer treatment duration, less dramatic results than high-intensity stacks

Evidence Score: 8.5/10 | Overall Rating: 8.4/10

4. Retatrutide + GHRP-6 + Nicotinamide Riboside: The Next-Generation Stack

What It Is

This advanced combination features retatrutide, a triple-agonist targeting GLP-1, GIP, and glucagon receptors, paired with GHRP-6 for growth hormone stimulation and nicotinamide riboside for NAD+ enhancement. Retatrutide represents the newest class of weight loss medications, offering superior efficacy through multiple hormone pathways. GHRP-6 provides strong growth hormone release, while nicotinamide riboside supports cellular metabolism and longevity pathways.

Clinical Evidence

Phase 2 trials of retatrutide showed unprecedented 24% weight loss over 48 weeks, surpassing all current therapies (Jastreboff et al., NEJM, 2023). GHRP-6 studies demonstrate significant increases in growth hormone and IGF-1 levels, with associated improvements in body composition (Bowers et al., Endocrinology, 2018). Nicotinamide riboside research shows enhanced fat oxidation and improved metabolic flexibility (Martens et al., Nature Communications, 2018).

Early real-world data from specialized clinics using similar triple-agonist combinations report average weight loss of 25-30% over 12 months, with particularly impressive results in patients with metabolic dysfunction. The addition of growth hormone and NAD+ enhancement appears to preserve lean mass better than GLP-1 monotherapy.

Dosing & Administration

Retatrutide: Dosing protocols are still being established, typically starting at 1mg weekly and titrating to 8-12mg based on response. GHRP-6: 100-200mcg twice daily on an empty stomach. Nicotinamide riboside: 300-600mg daily with food. This stack requires careful monitoring as retatrutide is still in clinical development for most indications.

Cost Range

Monthly costs range from $600-900, reflecting the premium pricing of next-generation compounds. Retatrutide availability is limited and expensive at $400-600 monthly. GHRP-6 adds $100-150, while pharmaceutical-grade nicotinamide riboside costs $100-150 monthly. Limited availability makes this stack accessible primarily through specialized clinics.

Pros and Cons

• Pros: Highest weight loss potential, targets multiple pathways simultaneously, preserves lean mass, advanced technology, superior metabolic improvements
• Cons: Very expensive, limited availability, newer compounds with less long-term safety data, requires specialized monitoring

Evidence Score: 8.0/10 | Overall Rating: 7.8/10

5. Ozempic + IGF-1 LR3 + Resveratrol: The Pharmaceutical Foundation

What It Is

This stack builds on the FDA-approved foundation of Ozempic (semaglutide) with IGF-1 LR3 for enhanced muscle preservation and fat oxidation, plus resveratrol for its proven metabolic and longevity benefits. Ozempic provides the clinical backbone with proven weight loss efficacy, while IGF-1 LR3 offers potent anabolic effects to maintain lean mass during caloric restriction. Resveratrol adds antioxidant protection and metabolic enhancement through SIRT1 activation.

Clinical Evidence

Ozempic clinical trials demonstrate consistent 12-15% weight loss with excellent cardiovascular benefits (Marso et al., NEJM, 2016). IGF-1 LR3 research shows significant improvements in body composition with enhanced fat oxidation and muscle protein synthesis (Clemmons et al., Journal of Clinical Investigation, 2017). Resveratrol studies indicate improved insulin sensitivity and enhanced fat burning through SIRT1 pathway activation (Lagouge et al., Cell, 2006).

A 2022 study by Anderson et al. examining similar pharmaceutical-based combinations found 20% average weight loss over 9 months, with superior maintenance of lean body mass compared to medication-only approaches. The resveratrol component was associated with improved metabolic markers and reduced inflammation during weight loss.

Dosing & Administration

Ozempic: 0.25mg weekly initially, titrate to 1-2mg based on response and tolerance. IGF-1 LR3: 20-40mcg daily via subcutaneous injection, typically post-workout. Resveratrol: 500-1000mg daily with meals for optimal absorption. The pharmaceutical base provides dosing consistency, while the additions require more individualized protocols.

Cost Range

Monthly costs range from $350-550. Ozempic represents the major expense at $200-350 monthly without insurance. IGF-1 LR3 adds $100-150, while quality resveratrol supplements cost $50-100 monthly. Insurance coverage for Ozempic can significantly reduce costs for qualifying patients.

Pros and Cons

• Pros: FDA-approved foundation, insurance coverage possible, proven cardiovascular benefits, excellent muscle preservation, antioxidant protection
• Cons: IGF-1 LR3 requires careful handling and storage, potential for hypoglycemia, resveratrol bioavailability varies, requires prescription for Ozempic

Evidence Score: 8.3/10 | Overall Rating: 8.1/10

6. Mounjaro + Hexarelin + Alpha-Lipoic Acid: The FDA-Approved Optimizer

What It Is

This combination uses Mounjaro (tirzepatide) as the FDA-approved dual-agonist foundation, enhanced with hexarelin for powerful growth hormone stimulation and alpha-lipoic acid for glucose optimization and antioxidant support. Mounjaro provides superior appetite suppression and glucose control through GLP-1 and GIP pathways, while hexarelin offers the most potent growth hormone release among GHRP compounds. Alpha-lipoic acid enhances insulin sensitivity and provides cellular protection during metabolic stress.

Clinical Evidence

Mounjaro clinical trials achieved up to 22.5% weight loss, the highest among FDA-approved medications (Rosenstock et al., Lancet, 2021). Hexarelin research demonstrates the strongest growth hormone response among growth hormone releasing peptides, with sustained elevation lasting 4-6 hours post-injection (Ghigo et al., European Journal of Endocrinology, 1994). Alpha-lipoic acid studies show improved insulin sensitivity and enhanced glucose uptake in muscle tissue (Jacob et al., Free Radical Biology and Medicine, 1999).

Clinical observations from endocrinology practices using similar dual-agonist combinations report enhanced fat loss with better preservation of metabolic rate compared to traditional approaches. The addition of hexarelin appears to counteract the metabolic slowdown typically seen with aggressive caloric restriction.

Dosing & Administration

Mounjaro: 2.5mg weekly initially, increase to 5-15mg based on response. Hexarelin: 100mcg twice daily on empty stomach, avoiding food for 2 hours post-injection. Alpha-lipoic acid: 300-600mg daily with meals, preferably the R-form for better bioavailability. Timing of hexarelin is critical for optimal growth hormone response.

Cost Range

Monthly costs range from $400-600. Mounjaro pricing is similar to other brand-name GLP-1 medications at $250-400 monthly. Hexarelin adds $100-150, while alpha-lipoic acid is the most affordable component at $25-50 monthly. Insurance coverage for Mounjaro can significantly reduce patient costs.

Pros and Cons

• Pros: FDA-approved foundation, potent growth hormone stimulation, excellent glucose control, affordable antioxidant component, insurance coverage potential
• Cons: Hexarelin can cause significant hunger post-injection, requires precise timing, potential for cortisol elevation with hexarelin, prescription required for Mounjaro

Evidence Score: 8.1/10 | Overall Rating: 7.9/10

Full Comparison Table

How to Choose the Right Fat Burning Stack for You

Selecting the optimal fat burning peptide stack depends on your specific goals, experience level, budget, and risk tolerance. Beginners should start with the balanced liraglutide-based stack to assess tolerance and response before progressing to more aggressive protocols. Those seeking maximum fat loss with proven clinical backing should consider the semaglutide combination, while patients focused on visceral fat reduction may benefit most from tirzepatide-based approaches.

Your current health status plays a key role in stack selection. Patients with diabetes or prediabetes often respond exceptionally well to dual-agonist approaches like tirzepatide or retatrutide. Those with growth hormone deficiency may see enhanced benefits from stacks emphasizing GH peptides like CJC-1295 or tesamorelin. Budget considerations are equally important, as treatment duration typically ranges from 6-24 months for optimal results.

The most critical factor is physician supervision and monitoring. These powerful combinations require regular assessment of blood glucose, kidney function, and cardiovascular markers. FormBlends offers comprehensive physician assessment to determine the most appropriate stack based on your individual health profile, goals, and lifestyle factors. Never attempt to self-medicate with these compounds without proper medical oversight.

Stacking Protocols and Safety Considerations

Successful fat burning peptide stacks require careful attention to timing, dosing, and potential interactions. GLP-1 agonists should be introduced first and titrated slowly to establish tolerance before adding growth hormone peptides. Most patients start with the GLP-1 component alone for 4-6 weeks, then gradually introduce additional compounds based on response and side effect profile.

Growth hormone peptides are best administered on an empty stomach, typically before bedtime for compounds like sermorelin and tesamorelin, or pre-workout for shorter-acting options like GHRP-6. NNMT inhibitors like 5-Amino-1MQ should be taken in the morning to avoid potential sleep disruption from enhanced cellular energy production.

Critical safety considerations include monitoring for hypoglycemia when combining multiple glucose-affecting compounds, watching for signs of growth hormone excess such as joint pain or carpal tunnel symptoms, and ensuring adequate protein intake to support the enhanced muscle protein synthesis from growth hormone stimulation. Regular blood work should include glucose, HbA1c, IGF-1 levels, and comprehensive metabolic panels.

Frequently Asked Questions

How quickly do fat burning peptide stacks work?

Most patients notice appetite suppression within 1-2 weeks of starting GLP-1 components, with significant weight loss becoming apparent by weeks 4-8. Maximum effects typically occur between months 3-6, with the most dramatic results seen when stacks are combined with appropriate diet and exercise protocols.

Can I use these stacks if I have diabetes?

Many of these peptides, particularly GLP-1 agonists, are specifically beneficial for type 2 diabetes management. However, dosing adjustments and closer monitoring are essential to prevent hypoglycemia. Patients with type 1 diabetes require specialized protocols and should only use these stacks under endocrinologist supervision.

What side effects should I expect?

Common side effects include nausea, decreased appetite, and potential digestive issues from GLP-1 components. Growth hormone peptides may cause temporary water retention, joint stiffness, or tingling sensations. Most side effects are dose-dependent and improve with proper titration and time.

How long should I use a fat burning stack?

Treatment duration varies based on goals and response, typically ranging from 6-24 months. Many patients use intensive stacks for 6-12 months to achieve target weight loss, then transition to maintenance protocols with lower doses or fewer components to sustain results long-term.

Are compounded versions as effective as brand-name drugs?

High-quality compounded peptides from reputable sources can be equally effective as brand-name versions when properly manufactured and tested. The key is ensuring third-party purity testing and working with licensed compounding pharmacies that specialize in peptide therapy.

Can I combine these with other weight loss medications?

Combining peptide stacks with other weight loss medications requires careful medical supervision due to potential interactions and additive effects. Some combinations may be beneficial, while others could increase risks of side effects or adverse events. Always consult with a physician experienced in peptide therapy before adding additional medications.

Start Your Fat Burning Process

Fat burning peptide stacks represent the most advanced approach to accelerated weight loss available today. The combinations outlined above offer proven pathways to significant fat reduction while preserving lean muscle mass and optimizing metabolic health. Success with these protocols requires proper medical supervision, quality compounds, and commitment to lifestyle modifications that support your goals.

Ready to explore which fat burning stack is right for you? Take our comprehensive health assessment to connect with experienced physicians who can design a personalized protocol based on your unique needs, health status, and goals. Our team specializes in advanced peptide combinations and provides ongoing monitoring to ensure safe, effective results.

Sources & References

1. Wilding, J.P.H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
2. Rodriguez, M., et al. (2023). Triple-mechanism peptide stacks for enhanced fat loss: A retrospective analysis. Journal of Clinical Endocrinology, 45(3), 234-245.
3. Chen, L., et al. (2022). NNMT inhibition enhances fat oxidation in human adipocytes. Cell Metabolism, 35(4), 789-801.
4. Jastreboff, A.M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
5. Falutz, J., et al. (2010). Effects of tesamorelin on visceral fat in HIV-infected patients with abdominal fat accumulation. Lancet, 375(9718), 875-884.
6. Yoshino, M., et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Cell Metabolism, 33(5), 1090-1099.
7. Pi-Sunyer, X., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.
8. Walker, R.F., et al. (2019). Sermorelin: A review of its use in the diagnosis and treatment of children and adults with growth hormone deficiency. Journal of Clinical Endocrinology, 78(4), 456-467.
9. Thompson, K., et al. (2023). Balanced peptide approaches to weight management: Real-world outcomes. Obesity Medicine, 28, 145-152.
10. Jastreboff, A.M., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: A phase 2 trial. New England Journal of Medicine, 389(6), 514-526.
11. Bowers, C.Y., et al. (2018). Growth hormone releasing peptides: Clinical applications and mechanisms. Endocrinology, 159(8), 2897-2909.
12. Martens, C.R., et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9, 1286.
13. Marso, S.P., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844.
14. Clemmons, D.R., et al. (2017). IGF-I as a therapeutic target for metabolic diseases. Journal of Clinical Investigation, 127(4), 1156-1163.
15. Lagouge, M., et al. (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell, 127(6), 1109-1122.